The RSI Indicator for ALKS moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In 18 of the 21 cases the stock moved higher. This puts the odds of a move higher at 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ALKS just turned positive on October 05, 2026. Looking at past instances where ALKS's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Following a +5.48% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in 201 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
ALKS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALKS as a result. In 65 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
The Aroon Indicator for ALKS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 51 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.824) is normal, around the industry mean (43.873). P/E Ratio (103.050) is within average values for comparable stocks, (141.710). ALKS's Projected Growth (PEG Ratio) (21.570) is very high in comparison to the industry average of (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (4.638) is also within normal values, averaging (178.797).
The Moving Average Convergence Divergence (MACD) for VTRS turned positive on October 16, 2026. Looking at past instances where VTRS's MACD turned positive, the stock continued to rise in 36 of 48 cases over the following month. The odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on VTRS as a result. In 56 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
VTRS moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VTRS crossed bullishly above the 50-day moving average on September 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +6.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where VTRS advanced for three days, in 223 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 190 of 278 cases where VTRS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VTRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
VTRS broke above its upper Bollinger Band on October 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. VTRS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.503) is normal, around the industry mean (43.873). P/E Ratio (-50.419) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (3.322) is also within normal values, averaging (2.152). VTRS has a moderately high Dividend Yield (0.026) as compared to the industry average of (0.005). P/S Ratio (1.347) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 35 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ALKS | VTRS | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 51 | 35 | |
SMR RATING 1..100 | 85 | 91 | |
PRICE GROWTH RATING 1..100 | 57 | 7 | |
P/E GROWTH RATING 1..100 | 2 | 1 | |
SEASONALITY SCORE 1..100 | 11 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VTRS's Valuation (12) in the null industry is significantly better than the same rating for ALKS (99) in the Biotechnology industry. This means that VTRS’s stock grew significantly faster than ALKS’s over the last 12 months.
VTRS's Profit vs Risk Rating (35) in the null industry is in the same range as ALKS (51) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.
ALKS's SMR Rating (85) in the Biotechnology industry is in the same range as VTRS (91) in the null industry. This means that ALKS’s stock grew similarly to VTRS’s over the last 12 months.
VTRS's Price Growth Rating (7) in the null industry is somewhat better than the same rating for ALKS (57) in the Biotechnology industry. This means that VTRS’s stock grew somewhat faster than ALKS’s over the last 12 months.
VTRS's P/E Growth Rating (1) in the null industry is in the same range as ALKS (2) in the Biotechnology industry. This means that VTRS’s stock grew similarly to ALKS’s over the last 12 months.
| ALKS | VTRS | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 86% | 3 days ago 58% |
| Stochastic ODDS (%) | 3 days ago 75% | 3 days ago 52% |
| Momentum ODDS (%) | 3 days ago 64% | 3 days ago 71% |
| MACD ODDS (%) | 3 days ago 70% | 3 days ago 75% |
| TrendWeek ODDS (%) | 3 days ago 72% | 3 days ago 71% |
| TrendMonth ODDS (%) | 3 days ago 61% | 3 days ago 67% |
| Advances ODDS (%) | 3 days ago 73% | 3 days ago 74% |
| Declines ODDS (%) | 5 days ago 65% | 6 days ago 64% |
| BollingerBands ODDS (%) | 3 days ago 69% | 3 days ago 53% |
| Aroon ODDS (%) | 3 days ago 53% | 3 days ago 68% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALKS’s FA Score shows that 1 FA rating(s) are green while VTRS’s FA Score has 3 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALKS’s TA Score shows that 5 TA indicator(s) are bullish while VTRS’s TA Score has 6 bullish TA indicator(s).
ALKS (@Pharmaceuticals: Generic) experienced а +1.50% price change this week, while VTRS (@Pharmaceuticals: Generic) price change was +5.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -6.95%. For the same industry, the average monthly price growth was -5.23%, and the average quarterly price growth was +10.96%.
ALKS is expected to report earnings on Oct 28, 2026.
VTRS is expected to report earnings on Nov 05, 2026.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
A.I.dvisor tells us that ALKS and NBIX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALKS and NBIX's prices will move in lockstep.
| Ticker / NAME | Correlation To ALKS | 1D Price Change % | ||
|---|---|---|---|---|
| ALKS | 100% | +2.79% | ||
| NBIX - ALKS | 31% Poorly correlated | -0.91% | ||
| VTRS - ALKS | 30% Poorly correlated | +2.39% | ||
| ACET - ALKS | 30% Poorly correlated | -11.09% | ||
| AMRX - ALKS | 27% Poorly correlated | -0.36% | ||
| LQDA - ALKS | 25% Poorly correlated | -1.24% | ||
More | ||||